Stephen Liu, MD| Medical Oncology ...

Dr. Stephen V. Liu

Claim this profile

MedStar Georgetown University Hospital

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
29 drugs studied

Area of expertise

1

Lung Cancer

Stephen V. Liu has run 10 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
ALK positive
2

Non-Small Cell Lung Cancer

Stephen V. Liu has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
Stage III

Affiliated Hospitals

Image of trial facility.

MedStar Georgetown University Hospital

Image of trial facility.

MedStar Washington Hospital Center

Clinical Trials Stephen V. Liu is currently running

Image of trial facility.

Durvalumab + Tremelimumab with Chemotherapy

for Non-Small Cell Lung Cancer

This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV infection.

Recruiting

1 award

Phase 2

18 criteria

Image of trial facility.

Repotrectinib

for Solid Tumors

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Recruiting

1 award

Phase 1 & 2

7 criteria

More about Stephen V. Liu

Clinical Trial Related

9 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Stephen V. Liu has experience with

  • Pembrolizumab
  • Carboplatin
  • Nivolumab
  • Paclitaxel
  • Pemetrexed
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Stephen V. Liu specialize in?

Is Stephen V. Liu currently recruiting for clinical trials?

Are there any treatments that Stephen V. Liu has studied deeply?

What is the best way to schedule an appointment with Stephen V. Liu?

What is the office address of Stephen V. Liu?

Is there any support for travel costs?